Riluzole for the treatment of acute traumatic spinal cord injury: rationale for and design of the NACTN Phase I clinical trial.

@article{Fehlings2012RiluzoleFT,
  title={Riluzole for the treatment of acute traumatic spinal cord injury: rationale for and design of the NACTN Phase I clinical trial.},
  author={Michael G. Fehlings and Jefferson R. Wilson and Ralph F. Frankowski and Elizabeth G Toups and Bizhan Aarabi and James Shields Harrop and Christopher I. Shaffrey and Susan J. Harkema and James David Guest and Charles Tator and Keith Dean Burau and Michele W Johnson and Robert G. Grossman},
  journal={Journal of neurosurgery. Spine},
  year={2012},
  volume={17 1 Suppl},
  pages={151-6}
}
In the immediate period after traumatic spinal cord injury (SCI) a variety of secondary injury mechanisms combine to gradually expand the initial lesion size, potentially leading to diminished neurological outcomes at long-term follow-up. Riluzole, a benzothiazole drug, which has neuroprotective properties based on sodium channel blockade and mitigation of… CONTINUE READING